



Multicenter, randomised clinical trial
comparing endoscopic **M**ucosal resection
(EMR) **A**nd endoscopic submucosal dissec**T**ion
(ESD) for resection of **L**arge **D**istal non-
pedunculated colorectal **A**denomas



gelre ziekenhuizen






MATILDA trial



Endoscopic Submucosal Dissection

- Classic ESD
- Hybrid ESD (hESD)



ESD has some important advantages


EMR

- Relatively easy
- ↓ Procedure time
- ↓ Complication rate
- ↓ R0-resection
- ↑ Recurrence rate



ESD

- Learning curve
- ↑ Procedure time
- ↑ Complication rate
- ↑ R0-resection
- ↓ Recurrence rate




Widely available




Not yet widely available
in Europe




Aim



We aim to evaluate the (cost-)effectiveness of ESD against EMR for resection of large colorectal adenomas on both short (i.e. 6 months) and long-term (i.e. 36 months)





Hypothesis




We hypothesize that in the short-run ESD is more time consuming resulting in higher healthcare costs, but is (cost-) effective and results in a lower patients burden on the long-term due to a higher number of R0-resections and lower recurrence rates with less need for repeated procedures.





* Only if recurrence is found at the 6-months colonoscopy, the next follow-up colonoscopy will be planned 6 months later (T=12 months). This is repeated until no recurrence is found with a maximum of three endoscopic resection attempts before referral to the surgeon.

Patients




Inclusion criteria:

- non-pedunculated polyp larger than 20 mm in the rectum, sigmoid or descending colon found during colonoscopy
- indication for endoscopic treatment
- ≥ 18 years old

Exclusion criteria:

- suspicion of malignancy as determined by endoscopic findings or proven malignancy at biopsy
- prior endoscopic resection attempt
- presence of synchronous distal advanced carcinoma that requires surgical resection
- the risk exceeds the benefit of endoscopic treatment, such as in patients with an extremely poor general condition or a very short life expectancy
- the inability to provide informed consent

Endpoints




Primary endpoint:

- Recurrence rate at follow-up colonoscopy after 6 months, observed from resected residual disease or, if not present, from biopsies of the scar

Secondary endpoints:

- Complete (R0-)resection rate, defined as dysplasia free vertical and lateral resection margins at histology
- Perceived burden and quality of life
- Complication rate
- Surgical referral rate defined as the number of patients that are referred for surgical management at 36 months
- Long-term recurrence rate at follow-up colonoscopy after 36 months, observed from resected residual disease or, if not present, from biopsies of the scar
- Health care resources and costs

Sample size




- calculated for the primary outcome parameters recurrence rate at 6 months
- recurrence rate: superiority model
 - 2% in the ESD group versus 12% in the EMR group
 - power of 80% and an α of 0.05
 - patients needed: 198
- Correct for patients lost-to-follow-up (7%) → **212 patients** will be included; 106 patients in each arm.

Datamanagement

- Research nurse from IKNL at each site
- Data-extraction from medical record & endoscopy form
- IKNL will send patients (digital) questionnaires on 6 timepoints:
 - baseline
 - 4 days after EMR/ESD
 - 4 weeks after EMR/ESD
 - after the 6 months follow-up colonoscopy
 - 13 months after EMR/ESD
 - after the 36 months follow-up colonoscopy

Don't forget... study procedures



- Experience level participating endoscopists
 - ESD: >25 colorectal ESDs
 - EMR: >500 EMRs with >50 in polyps ≥ 2 cm
- After pEMR: adjunct therapy with coagulation
- Opposite colonic wall will be marked with ink
- Resected specimen will be pinned on a paraffin, rubber or cork sheet
- No recurrence? Take biopsies!

gelre ziekenhuizen



MATILDA trial

